A detailed history of Invesco Ltd. transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 295,450 shares of ATXS stock, worth $2.69 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
295,450
Previous 11,488 2471.81%
Holding current value
$2.69 Million
Previous $88,000 4622.73%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$6.99 - $16.69 $1.98 Million - $4.74 Million
283,962 Added 2471.81%
295,450 $4.16 Million
Q4 2023

Feb 12, 2024

SELL
$4.42 - $8.06 $54,883 - $100,081
-12,417 Reduced 51.94%
11,488 $88,000
Q3 2023

Nov 13, 2023

BUY
$6.89 - $9.86 $77,505 - $110,915
11,249 Added 88.88%
23,905 $178,000
Q2 2023

Aug 11, 2023

BUY
$8.33 - $13.72 $105,424 - $173,640
12,656 New
12,656 $105,000

Others Institutions Holding ATXS

About Astria Therapeutics, Inc.


  • Ticker ATXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,178,000
  • Market Cap $138M
  • Description
  • Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...
More about ATXS
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.